Patient characteristics
| . | Present study (N = 60) . | Previous study9 (N = 28) . |
|---|---|---|
| Median age, y (range) | 57.5 (40-66) | 56 (33-64) |
| Sex ratio | 49 male/11 female | 23 male/5 female |
| Stage 3/4, no. (%) | 60/60 (100) | 28/28 (100) |
| B symptoms, no. (%) | 15/60 (25) | 14/28 (50) |
| PS > 1, no. (%) | 4/60 (7) | 0/28 (0) |
| LDH > N, no. (%) | 23/60 (38) | 12/28 (41) |
| β2-microglobulin > N, no. (%) | 18/38 (47) | 14/28 (50) |
| Median albumin, g/L (range) | 41 (26-60) | NA |
| Bone marrow involvement, no. (%) | 51/60 (85) | 25/28 (89) |
| Leukemic phase, no. (%) | 29/60 (48) | 14/28 (50) |
| Gastrointestinal involvement, no. (%) | 15/29 (52) | 11/23 (48) |
| MIPI, no. (%) | ||
| Low | 33/60 (55) | NA |
| Intermediate | 19/60 (32) | NA |
| High | 8/60 (13) | NA |
| . | Present study (N = 60) . | Previous study9 (N = 28) . |
|---|---|---|
| Median age, y (range) | 57.5 (40-66) | 56 (33-64) |
| Sex ratio | 49 male/11 female | 23 male/5 female |
| Stage 3/4, no. (%) | 60/60 (100) | 28/28 (100) |
| B symptoms, no. (%) | 15/60 (25) | 14/28 (50) |
| PS > 1, no. (%) | 4/60 (7) | 0/28 (0) |
| LDH > N, no. (%) | 23/60 (38) | 12/28 (41) |
| β2-microglobulin > N, no. (%) | 18/38 (47) | 14/28 (50) |
| Median albumin, g/L (range) | 41 (26-60) | NA |
| Bone marrow involvement, no. (%) | 51/60 (85) | 25/28 (89) |
| Leukemic phase, no. (%) | 29/60 (48) | 14/28 (50) |
| Gastrointestinal involvement, no. (%) | 15/29 (52) | 11/23 (48) |
| MIPI, no. (%) | ||
| Low | 33/60 (55) | NA |
| Intermediate | 19/60 (32) | NA |
| High | 8/60 (13) | NA |
NA indicates not applicable.